IRON · CIK 0001816736
What Disc Medicine, Inc. told the SEC could break it.
1 self-disclosed vulnerability, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for IRON. More may follow as additional filings are processed.
In its own words
What could break it.
Sole-source dependency
- Active pharmaceutical ingredients (API) for certain product candidates supplied from single-source suppliers — its sole sources of supplymedium
Disc Medicine depends on third parties for the supply of the active pharmaceutical ingredients (API) used in its product candidates, and those parties are its sole sources of supply for certain APIs — the loss of any of them could significantly harm its business. As a clinical-stage company advancing its lead program (bitopertin, in the registrational APOLLO trial for EPP/XLP) toward a potential accelerated approval, a disruption, capacity constraint, quality/regulatory issue, or termination at a single-source API supplier could delay clinical development and, if approved, commercial supply, with no qualified alternative readily available. Suppliers are unnamed, so this registers as a sole-source/single-supplier risk on the critical drug-substance input.
“The active pharmaceutical ingredients, or API, used in certain of our product candidates are supplied to us from single-source suppliers.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“In September 2019, we entered into an exclusive license agreement with AbbVie.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch